China's Innovent Biologics Raises $100 Million in C Round

Innovent Biologics of Suzhou announced a very significant $100 million C round funding, which the company will use to advance its portfolio of eight biologic drug candidates. Founded in 2011, Innovent already has one approved IND and four filed applications. The company's portfolio consists of a combination of innovative candidates and biosimilars. In addition, Innovent also offers biologic CMO services to other companies from its large EMEA/FDA/cGMP compliant facility in Suzhou's BioBay Park. Innovent's goal is to provide high quality biologic drugs to China at a reasonable price, with products in the oncology, diabetes and autoimmune sectors. More details.... Share this with colleagues: // //